5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.99▼ | 3.01▼ | 3.01▼ | 3.07▼ | 2.95▲ |
MA10 | 2.99▼ | 3.01▼ | 3.04▼ | 3.03▼ | 2.77▲ |
MA20 | 3.00▼ | 3.04▼ | 3.04▼ | 3.00▼ | 2.85▲ |
MA50 | 3.02▼ | 3.05▼ | 3.08▼ | 2.76▲ | 3.24▼ |
MA100 | 3.05▼ | 3.06▼ | 3.00▼ | 2.87▲ | 3.92▼ |
MA200 | 3.05▼ | 3.00▼ | 2.86▲ | 3.03▼ | 4.73▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.001▼ | -0.006▼ | -0.009▼ | -0.005▼ | 0.077▲ |
RSI | 38.661▼ | 39.985▼ | 40.434▼ | 51.382▲ | 50.979▲ |
STOCH | 62.917 | 37.331 | 26.668 | 68.141 | 52.372 |
WILL %R | -88.889▼ | -96.000▼ | -96.774▼ | -54.032 | -49.211 |
CCI | -108.381▼ | -132.013▼ | -164.227▼ | -5.577 | 76.150 |
Thursday, September 11, 2025 11:58 PM
Achieve Life Sciences (ACHV) said that Mark Rubinstein, M.D., will assume the role of Interim chief medical officer.
|
Thursday, September 11, 2025 02:23 PM
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence ...
|
Wednesday, September 03, 2025 05:42 AM
Filing based on pivotal Phase 3 ORCA-2 and ORCA-3 clinical trials demonstrating statistically significant and clinically meaningful smoking cessation FDA acceptance starts the review process and sets ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
17/09/25 | 3.05 | 3.085 | 2.96 | 2.965 | 480,186 |
16/09/25 | 3.05 | 3.12 | 3.0499 | 3.08 | 464,599 |
15/09/25 | 3.11 | 3.15 | 2.97 | 3.04 | 828,585 |
12/09/25 | 3.15 | 3.17 | 2.98 | 3.08 | 990,295 |
11/09/25 | 3.28 | 3.30 | 3.09 | 3.16 | 1,569,828 |
10/09/25 | 3.10 | 3.29 | 3.055 | 3.28 | 1,643,950 |
09/09/25 | 2.92 | 3.165 | 2.87 | 3.12 | 1,121,137 |
08/09/25 | 2.80 | 2.95 | 2.77 | 2.93 | 838,325 |
05/09/25 | 2.79 | 2.87 | 2.68 | 2.83 | 1,421,913 |
04/09/25 | 2.79 | 2.89 | 2.74 | 2.79 | 1,486,031 |
|
|
||||
|
|
||||
|
|